A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

Project: Research

Project Details

StatusActive
Effective start/end date28/05/25 → 27/05/27

Keywords

  • Clinical Trials
  • TAK-079-3002

Clinical Trial Phase

  • Phase III (a & b)